Inactive Instrument

Pfenex Inc. Stock price

Equities

PFNX

US7170711045

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Chief Operating Officer - 13-12-31
Director/Board Member 55 20-09-30
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member 51 20-09-30
Director/Board Member 55 20-09-30
Director/Board Member 54 20-09-30
More insiders
Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.
More about the company
  1. Stock
  2. Equities
  3. Stock Pfenex Inc. - Nyse